

Comparative efficacy of modified FOLFIRINOX, gemcitabine plus capecitabine and gemcitabine plus nab-paclitaxel as adjuvant treatment for resected pancreatic cancer: a Bayesian network meta-analysis

Victor Hugo Fonseca de Jesus and Rachel P Riechelmann

ecancer 15 1276 (2021) <https://doi.org/10.3332/ecancer.2021.1276>

Medical Oncology Department, A.C. Camargo Cancer Center, Rua Prof. Antônio Prudente 211, São Paulo SP 01509-010, Brazil

Throughout the text, please consider that the primary outcome of the PRODIGE24 trial was disease-free survival, and not overall survival.

Keywords: FOLFIRINOX, gemcitabine, capecitabine, nab-paclitaxel, adjuvant, pancreatic, cancer

Funding source

This study had no funding source.

Authors' contributions

Victor Hugo Fonseca de Jesus: conceptualisation, methodology, data curation, data analyses, writing and visualisation; Rachel Pimenta Riechelmann: methodology, writing and visualisation.

Correspondence to: Victor Hugo Fonseca de Jesus
Email: victor.jesus@accamargo.org.br

ecancer 2021, 15:1305
<https://doi.org/10.3332/ecancer.2021.1305>

Published: 12/10/2021
Received: 23/09/2021

Publication costs for this article were supported by ecancer (UK Charity number 1176307).

Copyright: © the authors; licensee ecancermedicalscience. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.